Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
Vasograin Plus represents a major advancement in the treatment of migraine
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Subscribe To Our Newsletter & Stay Updated